Agios Pharmaceuticals Inc (AGIO.O)
18 Sep 2014
|Market Cap (Mil.):||$1,597.13|
|Shares Outstanding (Mil.):||34.46|
- An experimental drug being developed by Agios Pharmaceuticals Inc showed promising anti-cancer activity in a tiny Phase I study of patients with relapsed acute myeloid leukemia (AML), according to data presented on Sunday.
April 6 - An experimental drug being developed by Agios Pharmaceuticals Inc showed promising anti-cancer activity in a tiny Phase I study of patients with relapsed acute myeloid leukemia (AML), according to data presented on Sunday.
|Pfizer Inc. (PFE.N)||$30.58||+0.23|
|Novartis AG (NOVN.VX)||CHF88.45||-0.45|
|Roche Holding Ltd. (ROG.VX)||CHF283.30||+2.50|
|Sanofi SA (SASY.PA)||€88.46||+0.93|
|AstraZeneca plc (AZN.L)||4,536.50p||+43.50|
|GlaxoSmithKline plc (GSK.L)||1,436.50p||+2.50|
|Eli Lilly and Co (LLY.N)||$66.59||+0.68|
|Shire PLC (SHP.L)||5,320.00p||-15.00|
|Shire PLC (3159084.L)||--||--|
|Alexion Pharmaceuticals, Inc. (ALXN.OQ)||$161.56||+0.03|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Agios Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Ford Investor Services, Inc.
Provider: Zacks Investment Research Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.